Mechanisms of B cell autoimmunity in SLE

Arthritis Research and Therapy

Volumn 13, Issue 5, 2011, Pages

  Dörner, Thomas ^a   Giesecke, Claudia ^a   Lipsky, Peter E ^b  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

B7 ANTIGEN; CD19 ANTIGEN; CD1D ANTIGEN; CD20 ANTIGEN; CD24 ANTIGEN; CD27 ANTIGEN; CD38 ANTIGEN; CD40 ANTIGEN; CD40 LIGAND; CD5 ANTIGEN; CD71 ANTIGEN; CD86 ANTIGEN; CD9 ANTIGEN; CHEMOKINE RECEPTOR CXCR3; CHEMOKINE RECEPTOR CXCR4; CHEMOKINE RECEPTOR CXCR5; COMMON ACUTE LYMPHOBLASTIC LEUKEMIA ANTIGEN; COMPLEMENT COMPONENT C3D RECEPTOR; FAS ANTIGEN; FAS LIGAND; FC RECEPTOR; HLA DR ANTIGEN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 10; INTERLEUKIN 21 RECEPTOR; L SELECTIN; MULTIDRUG RESISTANCE PROTEIN 1; NON RECEPTOR PROTEIN TYROSINE PHOSPHATASE 22; TUMOR NECROSIS FACTOR RECEPTOR; UNINDEXED DRUG;

ANCA ASSOCIATED VASCULITIS; ANTIGEN PRESENTING CELL; AUTOIMMUNE DISEASE; AUTOIMMUNE THROMBOCYTOPENIA; AUTOIMMUNITY; B LYMPHOCYTE; CELL ACTIVATION; CELL FUNCTION; HUMAN; MEMORY CELL; MULTIPLE SCLEROSIS; MYOSITIS; NONHUMAN; PLASMA CELL; REVIEW; SJOEGREN SYNDROME; SOMATIC HYPERMUTATION; SYSTEMIC LUPUS ERYTHEMATOSUS; ANIMAL; APOPTOSIS; IMMUNOLOGY; PATHOLOGY;

ANIMALS; APOPTOSIS; AUTOIMMUNE DISEASES; B-LYMPHOCYTES; HUMANS; LUPUS ERYTHEMATOSUS, SYSTEMIC;

EID: 81255146464     PISSN: 14786354     EISSN: 14786362     Source Type: Journal    
DOI: 10.1186/ar3433     Document Type: Review

References (81)

1. Townsend MJ, Monroe JG, Chan AC. B-cell targeted therapies in human autoimmune diseases: an updated perspective. Immunol Rev 2010, 237:264-283. 10.1111/j.1600-065X.2010.00945.x, 20727041.
2. Taylor KE, Chung SA, Graham RR, Ortmann WA, Lee AT, Langefeld CD, Jacob CO, Kamboh MI, Alarcón-Riquelme ME, Tsao BP, Moser KL, Gaffney PM, Harley JB, Petri M, Manzi S, Gregersen PK, Behrens TW, Criswell LA. Risk alleles for systemic lupus erythematosus in a large case-control collection and associations with clinical subphenotypes. Plos Genetics 2011, 7:e1001311. 10.1371/journal.pgen.1001311, 3040652, 21379322.
3. Lee HS, Bae SC. What can we learn from genetic studies of systemic lupus erythematosus? Implications of genetic heterogeneity among populations in SLE. Lupus 2010, 19:1452-1459. 10.1177/0961203310370350, 20947557.
4. Ozaki K, Spolski R, Ettinger R, Kim HP, Wang G, Qi CF, Hwu P, Shaffer DJ, Akilesh S, Roopenian DC, Morse HC, Lipsky PE, Leonard WJ. Regulation of B cell differentiation and plasma cell generation by IL-21, a novel inducer of blimp-1 and bcl-61. J Immunol 2004, 173:5361-5371.
5. Tavares RM, Turer EE, Liu CL, Advincula R, Scapini P, Rhee L, Barrera J, Lowell CA, Utz PJ, Malynn BA, Ma A. The ubiquitin modifying enzyme A20 restricts B cell survival and prevents autoimmunity. Immunity 2010, 33:181-191. 10.1016/j.immuni.2010.07.017, 2931361, 20705491.
6. Edwards JC, Cambridge G. B-cell targeting in rheumatoid arthritis and other autoimmune diseases. Nat Rev Immunol 2006, 6:394-403. 10.1038/nri1838, 16622478.
7. Dörner T, Isenberg D, Jayne D, Wiendl H, Zillikens D, Burmester G, . International Roundtable on B cells as Therapeutic Target for Intervention Current status on B-cell depletion therapy in autoimmune diseases other than rheumatoid arthritis. Autoimmun Rev 2009, 9:82-89. 10.1016/j.autrev.2009.08.007, 19716441, International Roundtable on B cells as Therapeutic Target for Intervention.
8. Merrill JT, Neuwelt CM, Wallace DJ, Shanahan JC, Latinis KM, Oates JC, Utset TO, Gordon C, Isenberg DA, Hsieh HJ, Zhang D, Brunetta PG. Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus: the randomized, double-blind, phase II/III systemic lupus erythematosus evaluation of rituximab trial. Arthritis Rheum 2010, 62:222-233. 10.1002/art.27233, 20039413.
9. Anolik JH, Barnard J, Owen T, Zheng B, Kemshetti S, Looney RJ, Sanz I. Delayed memory B cell recovery in peripheral blood and lymphoid tissue in systemic lupus erythematosus after B cell depletion therapy. Arthritis Rheum 2007, 56:3044-3056. 10.1002/art.22810, 17763423.
10. Dorner T, Jacobi AM, Lipsky PE. B cells in autoimmunity. Arthritis Res Ther 2009, 11:247. 10.1186/ar2780, 2787254, 19849820.
11. Lee J, Kuchen S, Fischer R, Chang S, Lipsky PE. Identification and characterization of a human CD5(+) pre-naive B cell population. J Immunol 2009, 182:4116-4126. 10.4049/jimmunol.0803391, 19299709.
12. Yurasov S, Tiller T, Tsuiji M, Velinzon K, Pascual V, Wardemann H, Nussenzweig MC. Persistent expression of autoantibodies in SLE patients in remission. J Exp Med 2006, 203:2255-2261. 10.1084/jem.20061446, 2118096, 16966430.
13. Yurasov S, Wardemann H, Hammersen J, Tsuiji M, Meffre E, Pascual V, Nussenzweig MC. Defective B cell tolerance checkpoints in systemic lupus erythematosus. J Exp Med 2005, 201:703-711. 10.1084/jem.20042251, 2212839, 15738055.
14. Odendahl M, Jacobi A, Hansen A, Feist E, Hiepe F, Burmester GR, Lipsky PE, Radbruch A, Dörner T. Disturbed peripheral B lymphocyte homeostasis in systemic lupus erythematosus. J Immunol 2000, 165:5970-5979.
15. Dorner T, Foster SJ, Farner NL, Lipsky PE. Immunoglobulin kappa chain receptor editing in systemic lupus erythematosus. J Clin Invest 1998, 102:688-694. 10.1172/JCI3113, 508930, 9710436.
16. Dorner T, Farner NL, Foster SJ, Lipsky PE. Immunoglobulin light chain usage in early SLE: Indications for receptor editing of both V kappa and V lambda light chains. Arthritis Rheum 1999, 42:S52.
17. Dorner T, Lipsky PE. Immunoglobulin variable-region gene usage in systemic autoimmune diseases. Arthritis Rheum 2001, 44:2715-2727. 10.1002/1529-0131(200112)44:12<2715::AID-ART458>3.0.CO;2-L, 11762931.
18. Alexander T, Thiel A, Rosen O, Massenkeil G, Sattler A, Kohler S, Mei H, Radtke H, Gromnica-Ihle E, Burmester GR, Arnold R, Radbruch A, Hiepe F. Depletion of autoreactive immunologic memory followed by autologous hematopoietic stem cell transplantation in patients with refractory SLE induces long-term remission through de novo generation of a juvenile and tolerant immune system. Blood 2009, 113:214-223. 10.1182/blood-2008-07-168286, 18824594.
19. Nimmerjahn F, Ravetch JV. Fc-receptors as regulators of immunity. Adv Immunol 2007, 96:179-204.
20. Ettinger R, Kuchen S, Lipsky PE. Interleukin 21 as a target of intervention in autoimmune disease. Ann Rheum Dis 2008, 67(Suppl 3):iii83-iii86.
21. Jacobi AM, Reiter K, Mackay M, Aranow C, Hiepe F, Radbruch A, Hansen A, Burmester GR, Diamond B, Lipsky PE, Dörner T. Activated memory B cell subsets correlate with disease activity in systemic lupus erythematosus-Delineation by expression of CD27, IgD, and CD95. Arthritis Rheum 2008, 58:1762-1773. 10.1002/art.23498, 18512812.
22. Wei C, Anolik J, Cappione A, Zheng B, Pugh-Bernard A, Brooks J, Lee EH, Milner EC, Sanz I. A new population of cells lacking expression of CD27 represents a notable component of the B cell memory compartment in systemic lupus erythematosus. J Immunol 2007, 178:6624-6633.
23. Klein U, Rajewsky K, Kuppers R. Human immunoglobulin (Ig)M(+)IgD(+) peripheral blood B cells expressing the CD27 cell surface antigen carry somatically mutated variable region genes: CD27 as a general marker for somatically mutated (memory) B cells. J Exp Med 1998, 188:1679-1689. 10.1084/jem.188.9.1679, 2212515, 9802980.
24. Fecteau JF, Cote G, Neron S. A new memory CD27(-)IgG(+) B cell population in peripheral blood expressing V-H genes with low frequency of somatic mutation. J Immunol 2006, 177:3728-3736.
25. Ma CS, Pittaluga S, Avery DT, Hare NJ, Maric I, Klion AD, Nichols KE, Tangye SG. Selective generation of functional somatically mutated IgM(+)CD27(+), but not Ig isotype-switched, memory B cells in X-linked lymphoproliferative disease. J Clin Invest 2006, 116:322-333. 10.1172/JCI25720, 1332028, 16424938.
26. Cappione A, Anolik JH, Pugh-Bernard A, Barnard J, Dutcher P, Silverman G, Sanz I. Germinal center exclusion of autoreactive B cells is defective in human systemic lupus erythematosus. J Clin Invest 2005, 115:3205-3216. 10.1172/JCI24179, 1242189, 16211091.
27. Yanaba K, Bouaziz JD, Haas KM, Poe JC, Fujimoto M, Tedder TF. A regulatory B cell subset with a unique CD1d(hi)CD5(+) phenotype controls T celldependent inflammatory responses. Immunity 2008, 28:639-650. 10.1016/j.immuni.2008.03.017, 18482568.
28. Bouaziz JD, Yanaba K, Venturi GM, Wang Y, Tisch RM, Poe JC, Tedder TF. Therapeutic B cell depletion impairs adaptive and autoreactive CD4(+) T cell activation in mice. Proc Natl Acad Sci USA 2007, 104:20878-20883. 10.1073/pnas.0709205105, 2409235, 18093919.
29. Blair PA, Noreña LY, Flores-Borja F, Rawlings DJ, Isenberg DA, Ehrenstein MR, Mauri C. CD19(+)CD24(hi)CD38(hi) B cells exhibit regulatory capacity in healthy individuals but are functionally impaired in systemic Lupus Erythematosus patients. Immunity 2010, 32:129-140. 10.1016/j.immuni.2009.11.009, 20079667.
30. Iwata Y, Matsushita T, Horikawa M, Dilillo DJ, Yanaba K, Venturi GM, Szabolcs PM, Bernstein SH, Magro CM, Williams AD, Hall RP, St Clair EW, Tedder TF. Characterization of a rare IL-10-competent B-cell subset in humans that parallels mouse regulatory B10 cells. Blood 2011, 117:530-541. 10.1182/blood-2010-07-294249, 20962324.
31. Odendahl M, Keitzer R, Wahn U, Hiepe F, Radbruch A, Dörner T, Bunikowski R. Perturbations of peripheral B lymphocyte homoeostasis in children with systemic lupus erythematosus. Ann Rheum Dis 2003, 62:851-858. 10.1136/ard.62.9.851, 1754662, 12922958.
32. Medina F, Segundo C, Campos-Caro A, Gonzalez-Garcia I, Brieva JA. The heterogeneity shown by human plasma cells from tonsil, blood, and bone marrow reveals graded stages of increasing maturity, but local profiles of adhesion molecule expression. Blood 2002, 99:2154-2161. 10.1182/blood.V99.6.2154, 11877292.
33. Odendahl M, Mei H, Hoyer BF, Jacobi AM, Hansen A, Muehlinghaus G, Berek C, Hiepe F, Manz R, Radbruch A, Dörner T. Generation of migratory antigenspecific plasma blasts and mobilization of resident plasma cells in a secondary immune response. Blood 2005, 105:1614-1621. 10.1182/blood-2004-07-2507, 15507523.
34. Mei HE, Yoshida T, Sime W, Hiepe F, Thiele K, Manz RA, Radbruch A, Dörner T. Blood-borne human plasma cells in steady state are derived from mucosal immune responses. Blood 2009, 113:2461-2469. 10.1182/blood-2008-04-153544, 18987362.
35. Arce E, Jackson DG, Gill MA, Bennett LB, Banchereau J, Pascual V. Increased frequency of pre-germinal center B cells and plasma cell precursors in the blood of children with systemic lupus erythematosus. J Immunol 2001, 167:2361-2369.
36. Grammer AC, Slota R, Fischer R, Gur H, Girschick H, Yarboro C, Illei GG, Lipsky PE. Abnormal germinal center reactions in systemic lupus erythematosus demonstrated by blockade of CD154-CD40 interactions. J Clin Invest 2003, 112:1506-1520. 259134, 14617752.
37. Illei GG, Shirota Y, Yarboro CH, Daruwalla J, Tackey E, Takada K, Fleisher T, Balow JE, Lipsky PE. Tocilizumab in systemic lupus erythematosus: data on safety, preliminary efficacy, and impact on circulating plasma cells from an open-label phase I dosage-escalation study. Arthritis Rheum 2010, 62:542-552. 10.1002/art.27221, 3057537, 20112381.
38. Jacobi AM, Odendahl M, Reiter K, Bruns A, Burmester GR, Radbruch A, Valet G, Lipsky PE, Dörner T. Correlation between circulating CD27(high) plasma cells and disease activity in patients with systemic lupus erythematosus. Arthritis Rheum 2003, 48:1332-1342. 10.1002/art.10949, 12746906.
39. Hutloff A, Büchner K, Reiter K, Baelde HJ, Odendahl M, Jacobi A, Dörner T, Kroczek RA. Involvement of inducible costimulator in the exaggerated memory B cell and plasma cell generation in systemic lupus erythematosus. Arthritis Rheum 2004, 50:3211-3220. 10.1002/art.20519, 15476242.
40. Goodnow CC, Sprent J, Fazekas de St Groth B, Vinuesa CG. Cellular and genetic mechanisms of self tolerance and autoimmunity. Nature 2005, 435:590-597. 10.1038/nature03724, 15931211.
41. Meffre E, Wardemann H. B-cell tolerance checkpoints in health and autoimmunity. Curr Opin Immunol 2008, 20:632-638. 10.1016/j.coi.2008.09.001, 18848883.
42. Wardemann H, Yurasov S, Schaefer A, Young JW, Meffre E, Nussenzweig MC. Predominant autoantibody production by early human B cell precursors. Science 2003, 301:1374-1377. 10.1126/science.1086907, 12920303.
43. Yurasov SV, Wardemann H, Hammersen J, Pascual V, Meffre E, Nussenzweig MC. Autoreactive B cells and immune tolerance alterations in peripheral blood of patients with systemic autoimmunity. Pediatric Research 2004, 55:292A.
44. Mietzner B, Tsuiji M, Scheid J, Velinzon K, Tiller T, Abraham K, Gonzalez JB, Pascual V, Stichweh D, Wardemann H, Nussenzweig MC. Autoreactive IgG memory antibodies in patients with systemic lupus erythematosus arise from nonreactive and polyreactive precursors. Proc Natl Acad Sci USA 2008, 105:9727-9732. 10.1073/pnas.0803644105, 2474524, 18621685.
45. Winkler TH, Fehr H, Kalden JR. Analysis of immunoglobulin variable region genes from human IgG anti-DNA hybridomas. Eur J Immunol 1992, 22:1719-1728. 10.1002/eji.1830220709, 1623920.
46. Davidson A, Manheimerlory A, Aranow C, Peterson R, Hannigan N, Diamond B. Molecular characterization of a somatically mutated anti-DNA antibody bearing two systemic lupus erythematosus-related idiotypes. J Clin Invest 1990, 85:1401-1409. 10.1172/JCI114584, 296585, 2110188.
47. Guo WZ, Smith D, Aviszus K, Detanico T, Heiser RA, Wysocki LJ. Somatic hypermutation as a generator of antinuclear antibodies in a murine model of systemic autoimmunity. J Exp Med 2010, 207:2225-2237. 10.1084/jem.20092712, 2947070, 20805563.
48. Breden F, Lepik C, Longo NS, Montero M, Lipsky PE, Scott JK. Comparison of antibody repertoires produced by HIV-1 infection, other chronic and acute infections, and systemic autoimmune disease. PLoS One 2011, 6:e16857. 10.1371/journal.pone.0016857, 3068138, 21479208.
49. Harley JB, Moser KL, Gaffney PM, Behrens TW. The genetics of human systemic lupus erythematosus. Curr Opin Immunol 1998, 10:690-696. 10.1016/S0952-7915(98)80090-3, 9914226.
50. Lulli P, Sebastiani GD, Trabace S, Passiu G, Cappellacci S, Porzio F, Morellini M, Cutrupi F, Galeazzi M. HLA antigens in Italian patients with systemic lupus erythematosus: evidence for the association of DQw2 with the autoantibody response to extractable nuclear antigens. Clin Exp Rheumatol 1991, 9:475-479.
51. Radbruch A, Muehlinghaus G, Luger EO, Inamine A, Smith KG, Dörner T, Hiepe F. Competence and competition: the challenge of becoming a long-lived plasma cell. Nat Rev Immunol 2006, 6:741-750. 10.1038/nri1886, 16977339.
52. Harley JB, Alarcón-Riquelme ME, Criswell LA, Jacob CO, Kimberly RP, Moser KL, Tsao BP, Vyse TJ, Langefeld CD, Nath SK, Guthridge JM, Cobb BL, Mirel DB, Marion MC, Williams AH, Divers J, Wang W, Frank SG, Namjou B, Gabriel SB, Lee AT, Gregersen PK, Behrens TW, Taylor KE, Fernando M, Zidovetzki R, Gaffney PM, Edberg JC, Rioux JD, Ojwang JO, James JA, Merrill JT, Gilkeson GS, Seldin MF, Yin H, Baechler EC, Li QZ, Wakeland EK, Bruner GR, Kaufman KM, Kelly JA. International Consortium for Systemic Lupus Erythematosus Genetics (SLEGEN) Genome-wide association scan in women with systemic lupus erythematosus identifies susceptibility variants in ITGAM, PXK, KIAA1542 and other loci. Nat Genet 2008, 40:204-210. 10.1038/ng.81, 18204446, International Consortium for Systemic Lupus Erythematosus Genetics (SLEGEN).
53. Jacobi AM, Mei H, Hoyer BF, Mumtaz IM, Thiele K, Radbruch A, Burmester GR, Hiepe F, Dörner T. HLA-DRhigh/CD27(high) plasmablasts indicate active disease in patients with systemic lupus erythematosus. Ann Rheum Dis 2010, 69:305-308. 10.1136/ard.2008.096495, 19196727.
54. Hutloff A, Dittrich AM, Beier KC, Eljaschewitsch B, Kraft R, Anagnostopoulos I, Kroczek RA. ICOS is an inducible T-cell co-stimulator structurally and functionally related to CD28. Nature 1999, 397:263-266. 10.1038/16717, 9930702.
55. Tokunaga M, Saito K, Kawabata D, Imura Y, Fujii T, Nakayamada S, Tsujimura S, Nawata M, Iwata S, Azuma T, Mimori T, Tanaka Y. Efficacy of rituximab (anti-CD20) for refractory systemic lupus erythematosus involving the central nervous system. Ann Rheum Dis 2007, 66:470-475. 1856059, 17107983.
56. O'Neill SK, Cao YX, Hamel KM, Doodes PD, Hutas G, Finnegan A. Expression of CD80/86 on B cells is essential for autoreactive T cell activation and the development of arthritis. J Immunol 2007, 179:5109-5116.
57. Vinuesa CG, Cook MC, Angelucci C, Athanasopoulos V, Rui L, Hill KM, Yu D, Domaschenz H, Whittle B, Lambe T, Roberts IS, Copley RR, Bell JI, Cornall RJ, Goodnow CC. A RING-type ubiquitin ligase family member required to repress follicular helper T cells and autoimmunity. Nature 2005, 435:452-458. 10.1038/nature03555, 15917799.
58. Bubier JA, Sproule TJ, Foreman O, Spolski R, Shaffer DJ, Morse HC, Leonard WJ, Roopenian DC. A critical role for IL-21 receptor signaling in the pathogenesis of systemic lupus erythematosus in BXSB-Yaa mice. Proc Natl Acad Sci USA 2009, 106:1518-1523. 10.1073/pnas.0807309106, 2635818, 19164519.
59. Avery DT, Deenick EK, Ma CS, Suryani S, Simpson N, Chew GY, Chan TD, Palendira U, Bustamante J, Boisson-Dupuis S, Choo S, Bleasel KE, Peake J, King C, French MA, Engelhard D, Al-Hajjar S, Al-Muhsen S, Magdorf K, Roesler J, Arkwright PD, Hissaria P, Riminton DS, Wong M, Brink R, Fulcher DA, Casanova JL, Cook MC, Tangye SG. B cell-intrinsic signaling through IL-21 receptor and STAT3 is required for establishing long-lived antibody responses in humans. J Exp Med 2010, 207:155-171. 10.1084/jem.20091706, 2812540, 20048285.
60. Johnston RJ, Poholek AC, DiToro D, Yusuf I, Eto D, Barnett B, Dent AL, Craft J, Crotty S. Bcl6 and Blimp-1 are reciprocal and antagonistic regulators of T follicular helper cell differentiation. Science 2009, 325:1006-1010. 10.1126/science.1175870, 2766560, 19608860.
61. Webb R, Wren JD, Jeffries M, Kelly JA, Kaufman KM, Tang Y, Frank MB, Merrill J, Kimberly RP, Edberg JC, Ramsey-Goldman R, Petri M, Reveille JD, Alarcón GS, Vilá LM, Alarcón-Riquelme ME, James JA, Vyse TJ, Moser KL, Gaffney PM, Gilkeson GS, Harley JB, Sawalha AH. Variants within MECP2, a key transcription regulator, are associated with increased susceptibility to lupus and differential gene expression in patients with systemic lupus erythematosus. Arthritis Rheum 2009, 60:1076-1084. 10.1002/art.24360, 2734382, 19333917.
62. Gottenberg JE, Cagnard N, Lucchesi C, Letourneur F, Mistou S, Lazure T, Jacques S, Ba N, Ittah M, Lepajolec C, Labetoulle M, Ardizzone M, Sibilia J, Fournier C, Chiocchia G, Mariette X. Activation of IFN pathways and plasmacytoid dendritic cell recruitment in target organs of primary Sjogren's syndrome. Proc Natl Acad Sci USA 2006, 103:2770-2775. 10.1073/pnas.0510837103, 1413808, 16477017.
63. Lindh E, Lind SM, Lindmark E, Hässler S, Perheentupa J, Peltonen L, Winqvist O, Karlsson MC. AIRE regulates T-cell-independent B-cell responses through BAFF. Proc Natl Acad Sci USA 2008, 105:18466-18471. 10.1073/pnas.0808205105, 2587634, 19011083.
64. Bernasconi NL, Traggiai E, Lanzavecchia A. Maintenance of serological memory by polyclonal activation of human memory B cells. Science 2002, 298:2199-2202. 10.1126/science.1076071, 12481138.
65. Teichmann LL, Ols ML, Kashgarian M, Reizis B, Kaplan DH, Shlomchik MJ. Dendritic cells in lupus are not required for activation of T and B cells but promote their expansion, resulting in tissue damage. Immunity 2010, 33:967-978. 10.1016/j.immuni.2010.11.025, 21167752.
66. Chan OT, Hannum LG, Haberman AM, Madaio MP, Shlomchik MJ. A novel mouse with B cells but lacking serum antibody reveals an antibody-independent role for B cells in murine lupus. J Exp Med 1999, 189:1639-1647. 10.1084/jem.189.10.1639, 2193634, 10330443.
67. Rönnblom L, Alm GV. A pivotal role for the natural interferon alphaproducing cells (plasmacytoid dendritic cells) in the pathogenesis of lupus. J Exp Med 2001, 194:F59-F63. 10.1084/jem.194.12.f59, 2193578, 11748288.
68. Sfikakis PP, Karali V, Lilakos K, Georgiou G, Panayiotidis P. Clonal expansion of B-cells in human systemic lupus erythematosus: evidence from studies before and after herapeutic B-cell depletion. Clin Immunol 2009, 132:19-31. 10.1016/j.clim.2009.02.010, 19345151.
69. Petersen-Mahrt SK, Harris RS, Neuberger MS. AID mutates E-coli suggesting a DNA deamination mechanism for antibody diversification. Nature 2002, 418:99-103.
70. Longo NS, Lugar PL, Yavuz S, Zhang W, Krijger PH, Russ DE, Jima DD, Dave SS, Grammer AC, Lipsky PE. Analysis of somatic hypermutation in X-linked hyper-IgM syndrome shows specific deficiencies in mutational targeting. Blood 2009, 113:3706-3715. 10.1182/blood-2008-10-183632, 2670789, 19023113.
71. Muñoz LE, Janko C, Schulze C, Schorn C, Sarter K, Schett G, Herrmann M. Autoimmunity and chronic inflammation - two clearance-related steps in the etiopathogenesis of SLE. Autoimmun Rev 2010, 10:38-42. 10.1016/j.autrev.2010.08.015, 20817127.
72. Herrmann M, Voll RE, Zoller OM, Hagenhofer M, Ponner BB, Kalden JR. Impaired phagocytosis of apoptotic cell material by monocyte-derived macrophages from patients with systemic lupus erythematosus. Arthritis Rheum 1998, 41:1241-1250. 10.1002/1529-0131(199807)41:7<1241::AID-ART15>3.0.CO;2-H, 9663482.
73. Baumann I, Kolowos W, Voll RE, Manger B, Gaipl U, Neuhuber WL, Kirchner T, Kalden JR, Herrmann M. Impaired uptake of apoptotic cells into tingible body macrophages in germinal centers of patients with systemic lupus erythematosus. Arthritis Rheum 2002, 46:191-201. 10.1002/1529-0131(200201)46:1<191::AID-ART10027>3.0.CO;2-K, 11817590.
74. Rovere P, Vallinoto C, Bondanza A, Crosti MC, Rescigno M, Ricciardi-Castagnoli P, Rugarli C, Manfredi AA. Bystander apoptosis triggers dendritic cell maturation and antigen-presenting function. J Immunol 1998, 161:4467-4471.
75. Gaipl US, Munoz LE, Grossmayer G, Lauber K, Franz S, Sarter K, Voll RE, Winkler T, Kuhn A, Kalden J, Kern P, Herrmann M. Clearance deficiency and systemic lupus erythematosus (SLE). J Autoimmun 2007, 28:114-121. 10.1016/j.jaut.2007.02.005, 17368845.
76. Jacobi AM, Huang W, Wang T, Freimuth W, Sanz I, Furie R, Mackay M, Aranow C, Diamond B, Davidson A. Effect of long-term belimumab treatment on B cells in systemic lupus erythematosus: extension of a phase II, doubleblind, placebo-controlled, dose-ranging study. Arthritis Rheum 2010, 62:201-210. 10.1002/art.27189, 2857977, 20039404.
77. Merrill JT, Buyon JP. Rituximab: wanted dead or alive. Arthritis Rheum 2010, 62:2188-2191. 10.1002/art.27544, 20506315.
78. Merrill JT, Burgos-Vargas R, Westhovens R, Chalmers A, D'Cruz D, Wallace DJ, Bae SC, Sigal L, Becker JC, Kelly S, Raghupathi K, Li T, Peng Y, Kinaszczuk M, Nash P. The efficacy and safety of abatacept in patients with non-life-threatening manifestations of systemic lupus erythematosus: results of a twelve-month, multicenter, exploratory, phase IIb, randomized, doubleblind, placebo-controlled trial. Arthritis Rheum 2010, 62:3077-3087. 10.1002/art.27601, 20533545.
79. Jacobi AM, Goldenberg DM, Hiepe F, Radbruch A, Burmester GR, Dorner T. Differential effects of epratuzumab on peripheral blood B cells of patients with systemic lupus erythematosus versus normal controls. Ann Rheum Dis 2008, 67:450-457.
80. Daridon C, Blassfeld D, Reiter K, Mei HE, Giesecke C, Goldenberg DM, Hansen A, Hostmann A, Frölich D, Dörner T. Epratuzumab targeting of CD22 affects adhesion molecule expression and migration of B-cells in systemic lupus erythematosus. Arthritis Res Ther 2010, 12:R204. 10.1186/ar3179, 3046510, 21050432.
81. Frölich D, Giesecke C, Mei HE, Reiter K, Daridon C, Lipsky PE, Dorner T. Secondary immunization generates clonally related antigen-specific plasma cells and memory B cells. J Immunol 2010, 185:3103-3110. 10.4049/jimmunol.1000911, 20693426.